Lirafugratinib (Lyrfigtu) Added to NCCN Guidelines as 2L Therapy for Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement
“The NCCN Guidelines are an important tool in helping clinicians determine the optimal treatment options for their patients,” said Rose Lai, M.D., senior vice president of clinical development at Elevar Therapeutics. “We are pleased that lirafugratinib was promptly added to the guidelines upon FDA approval.”
Share:
More News
“We are pleased with the outcome of our End-of-Phase 1 meeting with FDA and are confident in our development strategy for BH-30643 in EGFR C797S-positive NSCLC. Our planned Phase 2 trial, designed with registrational intent, builds on the encouraging clinical activity observed in SOLARA, where BH-30643 has demonstrated promising anti-tumor
Jai Rautela, Ph.D., MBA, Chief Executive Officer, Audax Biosciences, “Astellas shares our pioneering spirit in immuno-oncology making them an ideal partner for highly differentiated programs such as DAX-044. This partnership will expedite the planned phase 1 clinical evaluation of DAX-044 for the benefit of patients with various types of solid
“We are increasingly excited about the potential of zoci to provide an important new targeted therapeutic option for patients with multiple cancer types that commonly express DLL3, including epNECs,” said Rafael G. Amado, M.D., President, Head of Global Research and Development at Zai Lab. “We are pleased that results from
“FDA clearance of the IND for KT-300, a potential first-in-class TRIM7 inhibitor, is an important milestone for Kayak and brings our novel approach to RAS-driven cancers into the clinic,” said Josiah Hornblower, CEO of Kayak Therapeutics. “TRIM7 sits at a critical downstream node of the RTK–RAS signaling cascade, and its